CA3001699A1 - Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c - Google Patents

Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c Download PDF

Info

Publication number
CA3001699A1
CA3001699A1 CA3001699A CA3001699A CA3001699A1 CA 3001699 A1 CA3001699 A1 CA 3001699A1 CA 3001699 A CA3001699 A CA 3001699A CA 3001699 A CA3001699 A CA 3001699A CA 3001699 A1 CA3001699 A1 CA 3001699A1
Authority
CA
Canada
Prior art keywords
mitomycin
liposomes
doxorubicin
prodrug
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3001699A
Other languages
English (en)
French (fr)
Inventor
Alberto Gabizon
Patricia OHANA
Hilary Shmeeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shaare Zedek Scientific Ltd
Lipomedix Pharmaceuticals Ltd
Original Assignee
Shaare Zedek Scientific Ltd
Lipomedix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaare Zedek Scientific Ltd, Lipomedix Pharmaceuticals Ltd filed Critical Shaare Zedek Scientific Ltd
Publication of CA3001699A1 publication Critical patent/CA3001699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3001699A 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c Abandoned CA3001699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242097P 2015-10-15 2015-10-15
US62/242,097 2015-10-15
PCT/US2016/057176 WO2017066667A1 (en) 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Publications (1)

Publication Number Publication Date
CA3001699A1 true CA3001699A1 (en) 2017-04-20

Family

ID=57209906

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3001699A Abandoned CA3001699A1 (en) 2015-10-15 2016-10-14 Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin c

Country Status (6)

Country Link
US (1) US10617672B2 (https=)
EP (1) EP3362099A1 (https=)
JP (1) JP2018530623A (https=)
AU (1) AU2016337370A1 (https=)
CA (1) CA3001699A1 (https=)
WO (1) WO2017066667A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530623A (ja) 2015-10-15 2018-10-18 リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物
EP3853251A1 (en) * 2018-09-19 2021-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
CN109260155B (zh) * 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
AU2020207026A1 (en) * 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture
WO2021225113A1 (ja) * 2020-05-08 2021-11-11 国立大学法人京都工芸繊維大学 イオン性化学種濃縮方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation
PT2731591T (pt) * 2011-07-13 2020-09-18 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Lipossomas que coencapsulam um bisfosfonato e um agente anfipático
BR112014001346A8 (pt) * 2011-07-19 2018-05-08 Stc Unm composto nanotransportador, método, composto farmacêutico e uso de um composto
WO2013070872A1 (en) * 2011-11-08 2013-05-16 The Board Of Trustees Of The University Of Arkansas Methods and compositions for x-ray induced release from ph sensitive liposomes
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
WO2015191563A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c
JP2018530623A (ja) 2015-10-15 2018-10-18 リポメディックス・ファーマシューティカルズ・リミテッドＬｉｐｏｍｅｄｉｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． ドキソルビシンおよびマイトマイシンｃプロドラッグを共封入したリポソーム組成物

Also Published As

Publication number Publication date
US20180296529A1 (en) 2018-10-18
US10617672B2 (en) 2020-04-14
AU2016337370A1 (en) 2018-05-17
EP3362099A1 (en) 2018-08-22
JP2018530623A (ja) 2018-10-18
WO2017066667A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
EP3787607B1 (en) Carotenoid compositions and uses thereof
CN106466299B (zh) 以人参皂苷为膜材的空白脂质体、其制备方法及应用
JP5419716B2 (ja) オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US10617672B2 (en) Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C
JP2023538133A (ja) がん治療のための複数の切断可能なプロドラッグを含むナノ粒子
JP2010235634A (ja) リポソーム処方物
CN104582732A (zh) 治疗癌症的组合物及其制造方法
KR20140097215A (ko) 암 치료를 위한 조합 리포좀 조성물
RS20080388A (sr) Lečenje malignih bolesti
CN105188675A (zh) 经修饰多西他赛脂质体制剂
WO2014101356A1 (zh) 一种蟾毒灵脂质体及其制备方法和应用
CN115605196A (zh) 用于治疗癌症和癌症耐药性的脂质体制剂
EP3861987A1 (en) Combination medicine comprising drug-encapsulating liposome composition and platinum preparation
EP2384743A1 (en) Siosomal formulation for intracellular delivery and targeting of therapeutic agents
Orthmann et al. Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
JP7842015B2 (ja) リポソームアナマイシンによる肺標的抗癌療法
US20250064784A1 (en) Liposome composition comprising liposomal prodrug of mitomycin c and methods of treatment
KR102708349B1 (ko) 씨 알지디 에이씨피 케이로 변형된 장시간 순환 리포솜
WO2022153211A1 (en) Liposomal composition of a camptothecin derivative
US20170165382A1 (en) Nanocarriers for cancer treatment
Caddeo et al. A novel aminohydroxy sulfonamide formulated in PEGylated liposomes with potential antitumor activity
CN114746124A (zh) 包含活性剂沉淀物的递送系统复合物和使用方法
WO2025184543A1 (en) Compositions and methods for delivery of therapeutic compounds
HK40086650A (zh) 用於治疗癌症和癌症耐药性的脂质体制剂
WO2024108173A1 (en) Prodrug strategy that enhances efficacy and lowers systemic toxicity of mertansine

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230104